At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Bacillus Calmette-Guerin (BCG)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Bacillus Calmette-Guérin (BCG) Immunization on Cerebrospinal Fluid (CSF) and Blood-Based Biomarkers in Older Adults: A Pilot
In Brief
A Phase 2 clinical trial evaluating Bacillus Calmette-Guerin (BCG) for Healthy. Completed, enrolled 20 participants across 1 site.
Detailed Summary
A pilot study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartMar 2021
Primary CompletionDec 2022
TodayJul 2026
First PostedAug 11, 2020
Enrollment StartMar 1, 2021
Primary CompletionDec 9, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.9 years ago
Interventions
Bacillus Calmette-Guerin (BCG)biological
Vaccine